AVITA Medical, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US05380C1027
USD
3.55
-0.05 (-1.39%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About AVITA Medical, Inc. stock-summary
stock-summary
AVITA Medical, Inc.
Pharmaceuticals & Biotechnology
AVITA Medical Inc., formerly AVITA Therapeutics, Inc., is a regenerative medicine company with a technology platform to address medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. Its technology provides treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. It has developed RECELL System, a product for the treatment of acute thermal burn injuries in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, providing a way to treat severe burns that significantly reduces the amount of donor skin required. It can be used at the point of care alone or in combination with split-thickness skin autografts depending on the depth of the burn injury.
Company Coordinates stock-summary
Company Details
28159 Avenue Stanford, Suite 220 , VALENCIA CA : 91355
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 35 Schemes (15.63%)

Foreign Institutions

Held by 25 Foreign Institutions (2.92%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Lou Panaccio
Independent Non-Executive Chairman of the board
Dr. Michael Perry
Chief Executive Officer, Executive Director
Mr. Jeremy Cook
Independent Non-Executive Director
Prof. Suzanne Crowe
Independent Non-Executive Director
Mr. Louis Drapeau
Independent Non-Executive Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
18 Million
(Quarterly Results - Jun 2025)
Net Profit:
-10 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 112 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-2.06

stock-summary
Return on Equity

400.04%

stock-summary
Price to Book

-8.69